Shield Therapeutics is well positioned to become a fast growing, independent, international specialty pharmaceutical company.
WHO estimates of global prevalence of Iron Deficiency
Partnered with Norgine in Europe, Australia and New Zealand
40 million ID sufferers in Europe
Population of 1.4 billion people
Partnering process underway
10 million IDA patients in USA